Apollon
Cambridge, South Korea
◆ Total Raised
$3.8M
◆ Stage
series-a
◆ Location
Cambridge, South Korea
◆ Founded
2021
◆ Team size
11-50
◆ Links
◆ About Apollon
Developer of non-invasive continuous glucose monitoring (CGM) devices using Raman spectroscopy.
◆ What sets it apart
Uses targeted Raman spectroscopy to measure glucose non-invasively, avoiding needles, adhesive patches, and recurring consumables.
◆ Sectors
◆ Business
Modelhardware
CustomerPeople with diabetes and healthcare users who need continuous glucose monitoring
◆ Notable
- Published clinical validation showing accuracy comparable to FDA-cleared CGMs
- Built a global patent portfolio for Raman-based non-invasive CGM
- Advancing toward FDA De Novo regulatory submission
- Collaborated with MIT on clinical trials and development
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Apollon do?
Developer of non-invasive continuous glucose monitoring (CGM) devices using Raman spectroscopy.
Where is Apollon based?
Apollon is based in Cambridge, South Korea, founded in 2021.
How much has Apollon raised?
Apollon has raised $3.8M in tracked funding and is currently at the series-a stage.
Who has invested in Apollon?
Investors in Apollon include Not publicly confirmed from the website.